ADB-5'F-BUTINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist. It was synthesised as part of investigations into related compounds such as ADB-5'Br-BUTINACA and MDMB-5'Br-BUTINACA, and confirmed that fluorination of the indazole 5-position increases potency in a similar manner to bromination.[1]

ADB-5'F-BUTINACA
Identifiers
  • N-(1-amino-3,3-dimethyl-1-oxo-2-butanyl)-1-butyl-1H-5-fluoroindazole-3-carboxamide
Chemical and physical data
FormulaC18H25FN4O2
Molar mass348.422 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)c1nn(CCCC)c2ccc(F)cc21)C(C)(C)C
  • InChI=1S/C18H25FN4O2/c1-5-6-9-23-13-8-7-11(19)10-12(13)14(22-23)17(25)21-15(16(20)24)18(2,3)4/h7-8,10,15H,5-6,9H2,1-4H3,(H2,20,24)(H,21,25)/t15-/m1/s1
  • Key:JORGRORAECYNOJ-OAHLLOKOSA-N

See also

edit

References

edit
  1. ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.